Dupilumab for Uncontrolled COPD with Raised Eosinophils

NICE Technology Appraisals

Published March 26th, 2026

Detected March 26th, 2026

Summary

NICE has issued technology appraisal guidance TA1142 recommending dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and raised blood eosinophils. The guidance provides evidence-based recommendations for healthcare professionals.

View original document View source feed page

What changed

NICE has published final guidance TA1142 on the use of dupilumab (Dupixent) for the maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) in adults with elevated blood eosinophil counts. This guidance provides evidence-based recommendations for healthcare professionals regarding the appropriate use of this therapy.

Healthcare providers should consider these recommendations when treating eligible patients. The guidance also notes the existence of a commercial access agreement for dupilumab, with details available via the Commercial Access and Pricing (CAP) Portal for NHS organizations and a specific email address for non-NHS entities. Patients experiencing adverse events are advised to report them via the Yellow Card Scheme to the MHRA. Commissioners and providers are responsible for ensuring funding is available and for considering environmental impacts.

What to do next

Review NICE guidance TA1142 for recommendations on dupilumab use in COPD.
Consult the Commercial Access and Pricing (CAP) Portal for commercial arrangement details.
Report adverse events via the MHRA Yellow Card Scheme.

Source document (simplified)

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

Technology appraisal guidance
TA1142
Published:

26 March 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.

Last reviewed: 26 March 2026

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.